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Abstract This study systematically evaluates the TCGAwhole-transcriptome sequencing data of hepatocellular
carcinoma (HCC) by comparing the global gene expression proﬁles between tumors and their corresponding non-
tumorous liver tissue. Based on the differential gene expression analysis, we identiﬁed a number of novel
dysregulated genes, in addition to those previously reported. Top-listing upregulated (CENPF and FOXM1) and
downregulated (CLEC4G, CRHBP, and CLEC1B) genes were successfully validated using qPCR on our cohort of
65 pairs of human HCCs. Further examination for the mechanistic overview by subjecting signiﬁcantly
upregulated and downregulated genes to gene set enrichment analysis showed that different cellular pathways
were involved. This study provides useful information on the transcriptomic landscape and molecular mechanism
of hepatocarcinogenesis for development of new biomarkers and further in-depth characterization.
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Introduction
Hepatocellular carcinoma (HCC) is a common type of
cancer and one of the leading causes of cancer-related
mortality worldwide [1,2]. HCC is an aggressive malig-
nancy and patients with HCC have a poor prognosis.
Unfortunately, only a few effective treatment options are
available. Despite much effort in studying the molecular
mechanism of HCC carcinogenesis, current understanding
on this lethal disease is still limited.
In the past, delineating the underlying genome-wide
HCC regulatory and interaction networks primarily relied
on microarray-based technology [3–7]. Recent advance-
ment in next-generation sequencing facilitated the realiza-
tion of whole-transcriptome sequencing (WTS). This new
technological platform allows more comprehensive and
accurate examination of global gene expression proﬁle.
Currently, only a few studies have utilized WTS strategies
in delineating the transcriptomic landscape of HCC [8,9] or
liver cancer stem cells [10]. However, all of them are
limited by small sample size in providing a comprehensive
and representative overview of HCC transcriptome. The
Cancer Genome Atlas (http://cancergenome.nih.gov/)
represents a global collaboration in cancer research. It
has large collections of tissue samples, which were
examined in multiple aspects (e.g., genomic, transcrip-
tomic, and epigenetic). More importantly, the data are of
open access and freely available to all researchers for use in
their own studies. Therefore, the relatively large TCGA
HCC WTS data set was utilized in the discovery of the
current study.
In our study, we extractedWTS data from the collections
of free-access repositories from all 50 HCC cases, in which
tumorous (T) and their corresponding non-tumorous (NT)
liver tissue was available and analyzed by TCGA. We
compared global gene expression proﬁles between T and
NT liver tissue and identiﬁed differentially expressed (DE)
genes. Top-listing genes were validated by quantitative
PCR (qPCR) by using an independent sample cohort (n =
65). DE genes were then subjected to gene set enrichment
analysis, and we identiﬁed gene sets and signaling
pathways that were signiﬁcantly enriched with upregulated
and downregulated genes. These genes are attractive
molecular targets and are worthy of further investigation,
and they may be used as HCC biomarkers.
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Materials and methods
TCGAWTS data of HCC
From the TCGA data portal (http://cancergenome.nih.gov/),
we extracted all available WTS data of HCC (a total of 50
cases), which have both T and their corresponding NT
samples, through bulk download mode [liver HCC (cancer
type), RNASeqV2 (data type), level 3 (archive type) and
1.12.0 (data version)]. The data were generated based on
Illumina HiSeq 2000 platform and annotated to reference
transcript set of UCSC hg19 gene standard track. Gene
expression data were available as upper quartile normal-
ized RSEM count estimates. Extracted data were used
without further transformation, except by rounding off
values to integers.
Validation sample cohort of paired HCCs
A cohort of 65 surgically resected HCCs and their
corresponding NT livers were randomly selected for
validation. The specimens were collected from patients
who underwent surgical resection for HCC at Queen Mary
Hospital, Hong Kong. All of them were obtained
immediately after surgical resection, snap-frozen in liquid
nitrogen and kept at – 80°C. Each case had both frozen
tissue blocks and formalin-ﬁxed parafﬁn-embedded tissue;
frozen sections were cut from tumor blocks and stained for
histological examination to ensure a homogenous cell
population of tissue. The use of the tissue was approved by
the Institutional Review Board of the University of Hong
Kong/Hospital Authority Hong Kong West Cluster. The
demographic data of the patients are summarized in
Supplementary Table 1.
Differential gene expression detection
Differential gene expression (DGE) analysis was per-
formed using edgeR [11]. It uses negative binomial models
to capture variance dispersion for WTS read count data,
empirical Bayes estimation for gene-speciﬁc variation, and
generalized linear models applicable to general experi-
ments. As suggested by edgeR, genes with very low read
counts are usually not of interest in DGE analysis; hence,
average count-per-million (CPM) was used to determine
whether a gene was reasonably expressed or not.
Subsequently, log2(fold change), log2(CPM), statistical
signiﬁcance, and the corresponding false discovery rate
(FDR) were reported by edgeR. DE genes were selected
based on these parameters, with the T/NT expression fold
change (FC) denoting upregulation or downregulation.
Gene set enrichment analysis on DE genes
To evaluate the mechanistic overview of DGE for HCC,
the signiﬁcantly upregulated and downregulated genes
were tested for gene set or pathway enrichment by uGPA
package [12]. Enrichment analyses of the upregulated and
downregulated genes were performed separately as
recommended previously [13]. Curated gene sets were
obtained from MSigDB v4.0 (www.broadinstitute.org/
gsea/msigdb) and classiﬁed into functional gene sets
according to the domains of gene ontology (GO) [i.e.,
biological process (825 gene sets), cellular component
(233 gene sets), and molecular function (396 gene sets)] or
pathway gene sets according to canonical pathways as
documented by KEGG (186 gene sets). uGPA takes DGE
events as input and assesses them for enrichment events
within gene sets or signaling pathways by cumulative
hypergeometric test. An FDR of < 0.05 was treated as
signiﬁcant event.
Validation on top-listing gene candidates by qPCR in
human HCCs
To conﬁrm the WTS ﬁndings on DGE, the top-listing
upregulated (CENPF and FOXM1) and downregulated
(CLEC4G, CRHBP, and CLEC1B) genes were subjected
to qPCR by TaqMan real-time qPCR assays
(Hs01118845_m1, Hs01073586_m1, Hs00962163_g1,
Hs00181810_m1, and Hs00212925_m1), following man-
ufacturer’s instructions. Total RNAwas extracted by Trizol
(Invitrogen) and cDNA was synthesized by reverse
transcription kit (Life Technologies) on the validation
sample cohort (n = 65).
Results
Comparison of global gene expression proﬁles of HCC
T and NT tissue
By comparing the WTS read counts of the various genes
between T and NT tissue and subsequently applying the
selection criteria of log2(FC) ≥ 2, log2(CPM) ≥ 1, and
FDR < 0.05, 734 genes were regarded as having DGE,
among which 220 were upregulated and 514 were
downregulated (Fig. 1). In terms of statistical signiﬁcance,
CENPF (centromere protein F, 350/400 kDa) (log2FC =
3.64, FDR = 5.32E‒78) and CLEC4G (C-type lectin
domain family 4, member G) (log2FC = – 8.96, FDR =
1.19E‒80) were the most signiﬁcantly upregulated and
downregulated genes, respectively (Supplementary Tables
2 and 3).
Successful validation of top-listing candidates by qPCR
Top-listing upregulated (CENPF and FOXM1) and down-
regulated (CLEC4G, CRHBP, and CLEC1B) genes were
subjected to qPCR assays on our validation sample cohort
of 65 HCC pairs. All of these genes were found to be
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successfully validated (P < 0.0001, Mann-Whitney U
test) and the dysregulation trend matched with those
observed in the TCGAWTS data (Fig. 2).
Signiﬁcantly enriched pathways for upregulated and
downregulated genes
By subjecting the signiﬁcantly upregulated genes to
enrichment analysis on gene sets based on GO (i.e.,
biological process, cellular component, and molecular
function) and KEGG canonical pathways, we observed
that upregulated genes were signiﬁcantly enriched in
various domains (Table 1). For GO biological process, the
genes were mainly enriched in cell cycle processes. For
GO cellular component, non-membrane-bound organelles
and cytoskeleton were involved. For GO molecular
function, motor activity and various binding activities
were implicated. Based on the canonical signaling path-
ways documented in KEGG, pathways on cell cycle and
p53 signaling were signiﬁcantly enriched.
Meanwhile, downregulated genes were also subjected to
gene set enrichment analysis (Table 2). For GO biological
process, the genes were mainly related to signal transduc-
tion, response to stimulus, and various metabolic pro-
cesses. For GO cellular component, they were implicated
in membrane and extracellular matrix (ECM). For GO
molecular function, they were involved in versatile types
of activities including oxygen binding, receptor activity,
and oxidoreductase activity. They were also enriched in
canonical signaling pathways that are related to metabo-
lism of various substrates.
Discussion
In the current study, we made use of the T-NT TCGAWTS
data extracted from 50 HCC pairs to provide useful
transcriptomic landscape for HCC. We systematically
compared the gene expression proﬁles of HCC T samples
with their corresponding NT samples, and identiﬁed 734
Fig. 1 Volcano plot of the WTS data. The color of the data points denotes the status of DGE and the intensity (light vs. dark) and shape (round dot vs.
triangle) of the data points denote the average expression level of genes as deﬁned by log2(CPM) ( < 1 vs. ≥ 1).
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Fig. 2 Successful qPCR validation of top-listing DE genes.
Table 1 Summary of gene set enrichment analysis on signiﬁcantly upregulated genes
Gene set # of genes # of DE genes P value FDR DE genes
GO biological process
MITOTIC_CELL_CYCLE 153 27 6.91E – 33 5.70E – 30 PRC1, PKMYT1, AURKA, CDKN2A, CDKN2C,
CCNA2, CDCA5, MAD2L1, ZWINT, NEK2,
ANLN, NDC80, PLK1, E2F1, KIF23, KIF2C,
DLGAP5, CDC6, KIF11, UBE2C, BUB1B,
NCAPH, BUB1, CENPF, BIRC5, CENPE,
CDKN3
CELL_CYCLE_PROCESS 193 28 1.48E – 31 6.09E – 29 AURKA, CDCA5, CCNA2, MAD2L1, ZWINT,
NEK2, NDC80, CDC6, NCAPH, BUB1,
BIRC5, CDKN3, PRC1, PKMYT1, CDKN2A,
CDKN2C, ANLN, PLK1, E2F1, KIF23,
KIF2C, DLGAP5, KIF11, UBE2C, BUB1B,
CENPF, CENPE, RACGAP1
CELL_CYCLE_GO_0007049 315 32 6.90E – 31 1.90E – 28 AURKA, CCNA2, CDCA5, MAD2L1, ZWINT,
NEK2, NDC80, CDC20, CDT1, CDC6,
NCAPH, CDC45, BUB1, BIRC5, CDKN3,
PRC1, PKMYT1, CDKN2A, CDKN2C,
ANLN, PLK1, E2F1, KIF23, KIF2C,
DLGAP5, KIF11, MCM2, UBE2C, BUB1B,
CENPF, CENPE, RACGAP1
CELL_CYCLE_PHASE 170 25 2.02E – 28 4.17E – 26 PKMYT1, AURKA, CDKN2A, CDKN2C,
CDCA5, CCNA2, MAD2L1, ZWINT, NEK2,
ANLN, NDC80, PLK1, E2F1, KIF2C,
DLGAP5, CDC6, KIF11, UBE2C, BUB1B,
NCAPH, BUB1, CENPF, BIRC5, CENPE,
CDKN3
M_PHASE_OF_MITOTIC_CELL_CYCLE 85 19 1.49E – 25 2.45E – 23 PKMYT1, AURKA, KIF2C, DLGAP5, CDCA5,
CCNA2, KIF11, UBE2C, MAD2L1, ZWINT,
BUB1B, NEK2, ANLN, NCAPH, BUB1,
BIRC5, NDC80, CENPE, PLK1
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(Continued)
Gene set # of genes # of DE genes P value FDR DE genes
GO cellular component
NON_MEMBRANE_BOUND_
ORGANELLE
631 29 2.11E – 18 2.46E – 16 CDCA5, ZWINT, KIF4A, NDC80, MAPT, CDK1,
BUB1, CCNB2, PRC1, CDKN2A, ACTN2,
ANLN, PLK1, KIF23, KIF2C, DLGAP5,
KIF11, NEB, AURKA, MAD2L1, NEK2,
CDC20, CDT1, TOP2A, BIRC5, MCM2,
BUB1B, CENPF, CENPE
INTRACELLULAR_NON_MEMBRANE_
BOUND_ORGANELLE
631 29 2.11E – 18 2.46E – 16 CDCA5, ZWINT, KIF4A, NDC80, MAPT,
CDK1, BUB1, CCNB2, PRC1, CDKN2A,
ACTN2, ANLN, PLK1, KIF23, KIF2C,
DLGAP5, KIF11, NEB, AURKA, MAD2L1,
NEK2, CDC20, CDT1, TOP2A, BIRC5,
MCM2, BUB1B, CENPF, CENPE
MICROTUBULE_CYTOSKELETON 152 17 1.36E – 17 1.05E – 15 PRC1, AURKA, KIF4A, NEK2, CDC20, PLK1,
KIF23, KIF2C, DLGAP5, MAPT, TOP2A,
KIF11, CDK1, BUB1, CENPF, BIRC5,
CCNB2
SPINDLE 39 11 1.51E – 16 8.81E – 15 KIF23, KIF4A, PRC1, AURKA, DLGAP5,
BUB1, KIF11, CDK1, CENPF, BIRC5,
CDC20
CYTOSKELETAL_PART 235 18 1.29E – 15 6.03E – 14 AURKA, KIF4A, NEK2, CDC20, MAPT,
TOP2A, CDK1, BUB1, BIRC5, PRC1,
ACTN2, ANLN, PLK1, KIF23, KIF2C,
DLGAP5, KIF11, CENPF
GO molecular function
MICROTUBULE_MOTOR_ACTIVITY 16 5 1.96E – 08 7.77E – 06 KIF23, KIF4A, KIF11, CENPE, KIF2C
MOTOR_ACTIVITY 28 5 4.19E – 07 8.29E – 05 KIF23, KIF4A, KIF2C, KIF11, CENPE
CYTOSKELETAL_PROTEIN_BINDING 159 7 2.97E – 05 0.004 NRCAM, ACTN2, ANLN, MAPT, BIRC5,
RACGAP1, MAPK8IP2
CARBOHYDRATE_BINDING 72 5 4.90E – 05 0.005 REG3A, CD34, MDK, THBS4, LPL
PROTEIN_KINASE_REGULATOR_
ACTIVITY
39 4 6.21E – 05 0.005 SFN,CDKN2A,CDKN2C,MAPK8IP2
KEGG pathway
KEGG_CELL_CYCLE 128 19 6.25E – 22 1.16E – 19 CDC45, PLK1, CCNA2, BUB1, MCM2, PTTG1,
CDC6, CDC20, CCNB1, CCNE1, SFN, E2F1,
CDK1, BUB1B, MAD2L1, CDKN2A,
CDKN2C, PKMYT1, CCNB2
KEGG_OOCYTE_MEIOSIS 114 11 4.06E – 11 3.78E – 09 PLK1, BUB1, PTTG1, CDC20, CCNB1,
CCNE1, CDK1, MAD2L1, AURKA,
PKMYT1, CCNB2
KEGG_PROGESTERONE_MEDIATED_
OOCYTE_MATURATION
86 8 2.62E – 08 1.63E – 06 CDK1, MAD2L1, PLK1, CCNA2, BUB1,
PKMYT1, CCNB2, CCNB1
KEGG_P53_SIGNALING_PATHWAY 69 7 1.09E – 07 5.06E – 06 SFN, CDK1, CDKN2A, RRM2, CCNB2,
CCNB1, CCNE1
KEGG_TIGHT_JUNCTION 134 4 0.006 0.226 MYH4, ACTN2, CTNNA2, PPP2R2C
Table 2 Summary of gene set enrichment analysis on signiﬁcantly downregulated genes
Gene set # of genes # of DE genesP value FDR DE genes
GO biological process
SIGNAL_TRANSDUCTION 1634 70 9.98E – 19 8.24E – 16 DIRAS3, IGF1, IGF2, HPGD, GNA14, MARCO, CCL3,
ADRA2B, TBXA2R, ADRA1B, ADRA1A, WNK2, IL1RL1,
NR1I2, CXCL6, GRIA3, FCGR2B, GABRB3, CAMK2B,
BCL2L10, AVPR1A, TRPV4, CCL19, NPY1R, APOA1,
NR4A3, ESR1, CHRNA4, LILRB5, PDGFRA, ECM1,
TNFRSF11B, GADD45G, GADD45B, CLEC1B, IL18R1,
SOCS2, SOCS3, PTH1R, CTNND2, PTPRD, CRHBP, LIFR,
CEACAM6, FPR1, CXCL12, NR4A1, CXCL14, SKAP1,
WISP2, MCC, RND2, TACSTD2, EPHA2, NTRK2, TGFA,
CHL1, LY6E, VIPR1, CD79A, IGFBP1, PRKAR2B, RET,
RCAN1, ANXA3, SFRP5, SFRP1, GCGR, IGFALS, DTX1
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(Continued)
Gene set # of genes # of DE genesP value FDR DE genes
RESPONSE_TO_EXTERNAL_
STIMULUS
312 25 5.02E – 13 2.07E – 10 S100A8, SERPINE1, F9, SAA1, IL1RAP, TRPV4, CXCL2,
FPR1, CXCL6, GCGR, CCL21, LECT2, CCL19, CD1D,
ORM1, SELE, CXCL12, PGLYRP2, CCL3, ALB, LYVE1,
CXCL14, CXCL13, FOS, MBL2
CARBOXYLIC_ACID_
METABOLIC_PROCESS
178 19 2.13E – 12 5.38E – 10 SLC7A8, BBOX1, ASPA, GGT5, CYP39A1, ACOT12, GSTZ1,
SLC3A1, SDS, HAO2, AKR1D1, SLC27A5, GLS2, FTCD,
IGF1, CYP4A11, GLYAT, GCK, HPGD
ORGANIC_ACID_METABOLIC_
PROCESS
180 19 2.61E – 12 5.38E – 10 SLC7A8, BBOX1, ASPA, GGT5, CYP39A1, ACOT12, GSTZ1,
SLC3A1, SDS, HAO2, AKR1D1, SLC27A5, GLS2, FTCD,
IGF1, CYP4A11, GLYAT, GCK, HPGD
LIPID_METABOLIC_
PROCESS
325 24 8.36E – 12 1.38E – 09 CYP3A4, ALDH8A1, LCAT, APOF, PITPNM3, NR1I2,
CYP39A1, CETP, THRSP, HAO2, SLC27A5, HPGD,
APOA4, APOA1, BCO2, ACOT12, NPC1L1, IP6K3,
AKR1D1, CYP4A11, GLYAT, RDH16, UGT2B7, SMPD3
GO cellular component
MEMBRANE 1994 90 1.23E – 25 2.87E – 23 IL1RAP, GHR, SLC22A1, CFTR, SLC3A1, C8A, GNA14,
MARCO, ADRA2B, LYVE1, TBXA2R, ADRA1B, ADRA1A,
TREH, CA9, CD4, GPR128, ABCB11, STEAP4, CD163,
GRIA3, CD1D, SLC16A4, GABRB3, NAPSB, CNGA1,
PLEKHB1, PTPRS, AVPR1A, UNC93A, TRPV4, SELP,
NPY1R, SELE, SLC34A2, NCAM1, CNTFR, MRC1,
HS3ST3A1, MAN1C1, SLCO1B3, CHRNA4, CLEC4M,
PDGFRA, HS3ST3B1, CLEC1B, IL18R1, PKHD1, PTH1R,
RHBG, CR1, PTPRD, LIFR, SRPX, CEACAM6, C7, C9,
FPR1, STAB2, SLC13A2, CLDN2, PRSS8, GGT5, EPCAM,
TACSTD2, MME, EPHA2, NTRK2, CHL1, LY6E, PROM1,
VIPR1, FXYD1, ITGB8, ITGA9, CD79A, SLC5A1, NGFR,
PITPNM3, CDHR2, SLC7A8, KCND3, B3GAT1, SIGLEC7,
VSIG2,CLDN10, GCGR, SLC6A2, BASP1, SLC10A1
PLASMA_MEMBRANE 1426 75 2.65E – 25 3.09E – 23 LIFR, IL1RAP, CEACAM6, SLC22A1, GHR, CFTR, SLC3A1,
C9, FPR1, STAB2, GNA14, MARCO, ADRA2B, LYVE1,
ADRA1B, TBXA2R, SLC13A2, ADRA1A, TREH, CLDN2,
PRSS8, CD4, ABCB11, EPCAM, TACSTD2, MME, EPHA2,
NTRK2, STEAP4, CD163, LY6E, GRIA3, CD1D, PROM1,
SLC16A4, GABRB3, VIPR1, CNGA1, FXYD1, ITGB8,
ITGA9, CD79A, SLC5A1, NGFR, PTPRS, AVPR1A,
UNC93A, TRPV4, SELP, NPY1R, SELE, SLC7A8, KCND3,
SLC34A2, NCAM1, MRC1, SIGLEC7, SLCO1B3, CHRNA4,
CLEC4M, VSIG2, PDGFRA, HS3ST3B1, CLEC1B, CLDN10,
GCGR, IL18R1, SLC6A2, BASP1, PKHD1, PTH1R, RHBG,
CR1, PTPRD, SLC10A1
INTRINSIC_TO_MEMBRANE 1348 72 1.09E – 24 8.46E – 23 LIFR, IL1RAP, CEACAM6, SLC22A1, GHR, SLC3A1, C8A, C7,
C9, FPR1, STAB2, MARCO, ADRA2B, LYVE1, TBXA2R,
ADRA1B, ADRA1A, SLC13A2, TREH, CA9, GPR128,
ABCB11, GGT5, TACSTD2, MME, EPHA2, NTRK2,
CD163, CHL1, LY6E, CD1D, PROM1, SLC16A4, GABRB3,
VIPR1, CNGA1, FXYD1, ITGB8, ITGA9, SLC5A1,
PLEKHB1, NGFR, PTPRS, PITPNM3, CDHR2, AVPR1A,
SELP, NPY1R, SLC7A8, KCND3, SLC34A2, NCAM1, MRC1,
B3GAT1, SIGLEC7, HS3ST3A1, MAN1C1, SLCO1B3,
CHRNA4, CLEC4M, VSIG2, PDGFRA, HS3ST3B1,
CLEC1B, GCGR, SLC6A2, PKHD1, PTH1R, RHBG, CR1,
PTPRD, SLC10A1
INTEGRAL_TO_MEMBRANE 1330 70 1.21E – 23 7.03E – 22 LIFR, IL1RAP, CEACAM6, GHR, SLC22A1, SLC3A1, C8A, C7,
C9, FPR1, STAB2, MARCO, ADRA2B, LYVE1, ADRA1B,
TBXA2R, ADRA1A, SLC13A2, CA9, GPR128, ABCB11,
GGT5, TACSTD2, MME, EPHA2, NTRK2, CD163, CHL1,
LY6E, CD1D, PROM1, SLC16A4, GABRB3, VIPR1, CNGA1,
FXYD1, ITGB8, ITGA9, SLC5A1, PLEKHB1, NGFR, PTPRS,
PITPNM3, CDHR2, AVPR1A, SELP, NPY1R, SLC7A8,
KCND3, SLC34A2, NCAM1, MRC1, B3GAT1, SIGLEC7,
HS3ST3A1, MAN1C1, SLCO1B3, CHRNA4, CLEC4M,
VSIG2, PDGFRA, HS3ST3B1, CLEC1B, GCGR, SLC6A2,
PTH1R, RHBG, CR1, PTPRD, SLC10A1
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DE genes. A number of DE genes that were reported in
previous studies [8,9], such as ALG1L, SERPINA11,
TMEM82, GPC3, SPINK1, and ESM1, were also detected
in the current study. In addition, many other novel genes
were found to be signiﬁcantly upregulated (Supplementary
Table 2) and downregulated (Supplementary Table 3).
CENPF (centromere protein F) and FOXM1 (forkhead box
M1) were among the top-listing signiﬁcantly upregulated
genes. CENPF is required for kinetochore function and
chromosome segregation in mitosis. On the other hand,
(Continued)
Gene set # of genes # of DE genesP value FDR DE genes
MEMBRANE_PART 1670 78 4.27E – 23 1.99E – 21 IL1RAP, SLC22A1, GHR, CFTR, SLC3A1, C8A, GNA14,
MARCO, ADRA2B, LYVE1, TBXA2R, ADRA1B, ADRA1A,
TREH, CA9, GPR128, ABCB11, CD163, CD1D, SLC16A4,
GABRB3, CNGA1, PLEKHB1, PTPRS, AVPR1A, SELP,
NPY1R, SLC34A2, NCAM1, CNTFR, MRC1, HS3ST3A1,
MAN1C1, SLCO1B3, CHRNA4, CLEC4M, PDGFRA,
HS3ST3B1, CLEC1B, PKHD1, PTH1R, RHBG, CR1,
PTPRD, LIFR, CEACAM6, C7, C9, FPR1, STAB2,
SLC13A2, CLDN2, GGT5, TACSTD2, MME, EPHA2,
NTRK2, CHL1, LY6E, PROM1, VIPR1, FXYD1, ITGB8,
ITGA9, CD79A, SLC5A1, NGFR, PITPNM3, CDHR2,
SLC7A8, KCND3, B3GAT1, SIGLEC7, VSIG2, CLDN10,
GCGR, SLC6A2, SLC10A1
GO molecular function
OXYGEN_BINDING 22 12 9.98E – 18 3.95E – 15 CYP3A4, CYP3A7, CYP1A1, CYP2C19, CYP26A1, CYP1A2,
CYP2E1, ALB, CYP2A6, CYP2A7, CYP8B1, HBB
RECEPTOR_ACTIVITY 583 34 3.28E – 13 6.50E – 11 LIFR, PTPRS, AVPR1A, IL13RA2, GHR, FPR1, STAB2, HPGD,
MARCO, PGLYRP2, RET, CNTFR, ADRA2B, GABRP, MRC1,
NR4A3, ADRA1B, TBXA2R, ADRA1A, SIGLEC7, MCC, CD4,
GPR128, CHRNA4, LILRB5, TACSTD2, PDGFRA,
TNFRSF11B, CLEC1B, GCGR, GABRB3, VIPR1, PTH1R,
PTPRD
OXIDOREDUCTASE_ACTIVITY 289 24 6.83E – 13 9.02E – 11 CYP3A4, ALDH8A1, BBOX1, CYP26A1, CYP1A2, GPD1,
CYP8B1, CYP39A1, GSTZ1, HAO2, PHGDH, HPGD,
ADH1B, AKR7A3, KMO, BCO2, TDO2, SRD5A2, ACADL,
CYP2A6, ADH6, ADH4, CYP4A11, RDH16
TRANSMEMBRANE_
RECEPTOR_ACTIVITY
418 25 2.78E – 10 2.75E – 08 LIFR, PTPRS, AVPR1A, IL13RA2, GHR, FPR1, STAB2, HPGD,
CNTFR, ADRA2B, GABRP, ADRA1B, TBXA2R, ADRA1A,
CD4, GPR128, CHRNA4, LILRB5, PDGFRA, CLEC1B,
GCGR, GABRB3, VIPR1, PTH1R, PTPRD
RECEPTOR_BINDING 377 23 9.87E – 10 7.82E – 08 APOF, PITPNM3 ,IL1RN, TNFRSF11B, SAA1, TGFA, CXCL2,
CXCL6, CCL21, CCL19, IGF1, IGF2, CXCL12, APOA1,
SOCS2, CCL3, ANGPTL1, CXCL14, CXCL13, MBL2,
ADAMTS13, TNXB, DTX1
KEGG pathway
KEGG_RETINOL_METABOLISM 64 25 6.92E – 31 1.29E – 28 CYP4A11, CYP3A4, ADH1B, ADH1C, ADH4, ADH1A,
CYP26A1, CYP2C9, CYP2C19, CYP2C8, CYP2B6,
CYP2A13, UGT1A4, CYP3A7, LRAT, CYP2A6, CYP2A7,
CYP4A22, CYP1A1, CYP1A2, ADH6, UGT2A1, CYP3A43,
RDH16, UGT2B7
KEGG_DRUG_METABOLISM_
CYTOCHROME_P450
72 23 4.00E – 26 3.72E – 24 CYP2E1, CYP3A4,GSTZ1, ADH1B, ADH1C, ADH4, ADH1A,
CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2A13, UGT1A4,
CYP3A7, GSTM5, GSTA2, CYP2A6, CYP2A7, CYP1A2,
ADH6, UGT2A1, CYP3A43, UGT2B7
KEGG_METABOLISM_OF_
XENOBIOTICS_BY_
CYTOCHROME_P450
70 21 2.63E – 23 1.63E – 21 CYP2E1, CYP3A4, GSTZ1, ADH1B, ADH1C, ADH4, ADH1A,
CYP2C9, CYP2C19, CYP2C8, CYP2B6, UGT1A4, CYP3A7,
GSTM5, GSTA2, CYP1A1, CYP1A2, ADH6, UGT2A1,
CYP3A43, UGT2B7
KEGG_DRUG_METABOLISM_
OTHER_ENZYMES
51 12 1.75E – 12 8.13E – 11 CYP3A4, UPP2, CDA, CYP2A13, UGT1A4, CYP3A7, CYP2A6,
CYP2A7, UGT2A1, CYP3A43, NAT2, UGT2B7
KEGG_LINOLEIC_ACID_
METABOLISM
29 9 6.96E – 11 2.59E – 09 CYP2E1, CYP3A4, CYP1A2, PLA2G2A, CYP3A43, CYP2C9,
CYP2C19, CYP2C8, CYP3A7
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FOXM1 is a transcription factor that regulates the
expression of cell cycle genes for DNA replication and
mitosis. It may also have roles in controlling cell
proliferation and DNA-break repair of DNA damage
checkpoint response. Intriguingly, through an integrative
computational approach in which the interactomes of
human and mice were compared, CENPF and FOXM1
were predicted to be the master regulators for prostate
cancer malignancy [14]. Moreover, they were also shown
to act synergistically in driving aggressive prostate cancer.
Knockdown of CENPF and FOXM1 synergistically
reduced the proliferation of prostate cancer cells and
tumor growth in cell-line-derived xenografts. It was further
shown that knockdown of CENPF expression reduced the
binding of FOXM1 to its targets. These two proteins were
also demonstrated to co-localize in nucleus and their co-
expression was a robust prognostic indicator of poor
survival and metastasis. Thus, the concurrent upregulation
of them in HCC likely suggests a similar synergistic co-
operation in hepatocarcinogenesis.
Among the most signiﬁcantly downregulated genes, we
noted multiple members of the C-type lectin family
(CLEC4G, CLEC1B, and CLEC4M) and CRHBP [cortico-
tropin-releasing factor (CRF) binding protein]. C-type
lectins are calcium-dependent glycan binding proteins and
function as adhesion and signaling receptors in various
immune functions, including inﬂammation and immunity
to tumor and virally infected cells [15]. According to the
Human Protein Atlas [16], CLEC4G, CLEC1B, and
CLEC4M are predominantly expressed in liver; however,
CLEC4G and CLEC4M are expressed at very low levels or
are undetectable in liver cancer tissue (data not available
for CLEC1B on liver cancer tissue). This ﬁnding suggests
that disruption of expression of these C-type lectin proteins
may have a role in the pathogenesis of HCC. CRHBP is a
member of the CRF system. Activation of CRF receptors,
particularly CRFR2 was shown to inhibit tumor progres-
sion, modulate proliferation and apoptosis, and interfere
with angiogenesis through reduction of VEGF expression
in vivo in various cancers [17–20]. A recent study also
indicated that reduced expression of CRHBP was asso-
ciated with a more aggressive behavior of human kidney
cancer, suggesting depletion of CRHBP may be involved
in renal carcinogenesis [21].
Gene set enrichment analysis further provides a
mechanistic overview of HCC. First, proteins of various
cell cycle processes were frequently upregulated, particu-
larly for multiple cyclins and cyclin-dependent kinases
(CCNA2, CCNB1, CCNB2, CCNE1, CDK1, CDKN2A,
CDKN2C, and CDKN3) (Supplementary Tables 2 and 4).
Given that cell cycle is controlled at various checkpoints
by regulating cyclins, cyclin-dependent kinases and other
cell cycle proteins [22,23], upregulation of these genes
may lead to disruption in cell cycle control and result in
abnormal cell proliferation. Second, the expression of
many genes for various metabolic processes was prefer-
entially downregulated in HCC, including metabolism of
retinol, fatty acids, amino acids and carbohydrates, steroid
hormone biosynthesis, and glycolysis and gluconeogen-
esis. In particular, multiple components of cytochrome
P450 were signiﬁcantly downregulated in HCC (Supple-
mentary Tables 3 and 5) and they play critical roles in
biosynthesis and metabolism [24]. Besides, they are also
involved in the removal of toxic substances from the body
[25,26]. Meanwhile, numerous cytokines (CCLs and
CXCLs) were also downregulated in HCC (Supplementary
Tables 3 and 5). Cytokines and its receptors are important
for triggering immune responses through the action of
various immune cells [27]. These immune responses are
critical in responses against infection [28] and cancer [29].
Overall, these ﬁndings suggest altered metabolic and
immune systems of HCC compared with non-tumorous
hepatocytes.
In the initial global analyses of the TCGAWTS data of
HCC and subsequent validation by an independent sample
cohort, we discovered several promising gene candidates
and pathways that are signiﬁcantly dysregulated in HCC.
These ﬁndings shed light on some novel targets that may
potentially drive hepatocarcinogenesis. However, further
functional characterization and in vivo validation using
animal model are needed to substantiate our ﬁndings.
In conclusion, this study explored the molecular
mechanism of hepatocarcinogenesis through assessment
of TCGAWTS data of HCC and validation of some of the
top-listing DE genes in an independent cohort. It provides
useful information on the transcriptomic landscape as well
as a mechanistic overview of HCC. Our ﬁndings offer
novel insights and useful support in biomarker develop-
ment and suggest new potential targets in HCC character-
ization.
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